Luke Ostapchuk

With the baby boomer generation starting to retire en masse, combined with a steadily declining fertility rate, national pension plans around the world are approaching a crisis.

The longevity industry just got a huge boost, coming from a place you may least expect – the halls of Washington.

These books focus on the current scientific research surrounding how and why we age. They also serve as great introductions for readers looking for a foundational base of aging industry insights.

The Spannr Longevity Stock Index was introduced in 2022 as the first index of its kind to provide real-time tracking of the entire public longevity market. The index was launched in May 2022 and the previous quarter, Q4, marks only the second full quarter of the index being live and operational. In this report, we ...

The past year has been pretty epic for us folks interested in defying aging. Aside from Spannr officially launching (we know, big deal), there’s been many developments in the space that we can all hang our hats on. But before we even go there, let’s first take a step back… The Bigger Picture Longevity… Biotech… ...

November’s Funding Roundup: $602.5M Raised Across 14 Funding Rounds Jnana Therapeutics, a biotech company leveraging its chemoproteomics platform to discover medicines for challenging-to-drug targets, raises $107 Million Series C from Bain Capital Life Sciences with participation from RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures & Pfizer Ventures Nymbl Science, a digital balance trainer, ...

The Longevity Biotech Fellowship (LBF) – a non-profit community aiming to bring people together to help progress the revolutionary field of longevity – is back, opening its doors to a new cohort of entrepreneurs, students, and investors. The upcoming program that’s set to launch in January 2023 represents LBF’s third cohort since its inception. Applications ...

NMN supplements, a market estimated to be worth $280.2 million this year, just got a no-go from the FDA, curbing many “anti-aging” supplement providers and longevity enthusiasts from interacting with one of the most popular longevity supplements on the market. While the news has stirred up a bit of drama and finger-pointing, which we’ll eventually ...

October’s Longevity Funding Roundup: $446M Raised Across 10 Funding Rounds PreComb Therapeutics, a company developing an evidence-based therapy prediction for cancer drug discovery and therapy guidance, closes 1.3 million CHF Pre-Series A Round led by LongeVC and Kinled Form Bio, a spin-out from Colossal Biosciences that offers an advanced, comprehensive software platform that replaces cumbersome, ...